DDInter111 DDInter1435
Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Apremilast {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Apremilast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betrixaban
Apremilast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Apremilast {u} may lead to a major life threatening interaction when taken with {v} Fosphenytoin
Apremilast {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Apremilast may cause a minor interaction that can limit clinical effects when taken with Modafinil
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin
Apremilast may lead to a major life threatening interaction when taken with Fosphenytoin
Apremilast may lead to a major life threatening interaction when taken with Enzalutamide